Q-omics provides the consensus-scored CYLC1 profile across patient tissues and cancer cell-line models. CYLC1 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, CYLC1 is differentially expressed in 1, with the highest sampling consensus in KICH. Additionally, CYLC1 RNA expression shows 5,804 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THYM, KICH, and STAD as cancer lineages where CYLC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYLC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYLC1 survival associations across molecular data types. CYLC1 RNA expression shows survival associations in the most cancer types (11), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYLC1 RNA expression–survival associations across cancer types. High CYLC1 expression shows unfavorable associations in THYM, BRCA, STAD, ESCA, COAD and LGG. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for CYLC1 RNA expression.
This table summarizes CYLC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CYLC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYLC1 shows higher tumor expression in KICH. The KICH box plot shows higher CYLC1 RNA expression in tumor versus normal tissue (log2 FC = +0.238, t-test p = .006).
This table shows molecular features associated with CYLC1 in patient tissues and cancer cell lines. In patient samples, CYLC1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CYLC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
